Suppr超能文献

熊去氧胆酸治疗及内镜扩张术对原发性硬化性胆管炎主胆管狭窄的疗效:一项为期8年的前瞻性研究

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.

作者信息

Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L

机构信息

Department of Medicine, University of Heidelberg, FRG.

出版信息

J Hepatol. 1997 Mar;26(3):560-6. doi: 10.1016/s0168-8278(97)80421-7.

Abstract

BACKGROUND/AIMS: Primary sclerosing cholangitis is characterized by progressive fibrotic inflammation and obliteration of intra- and extrahepatic bile ducts. Ursodeoxycholic acid treatment leads to improvement of biochemical parameters of cholestasis and in part also of liver histology. During treatment, obstruction of major ducts may lead to deterioration of liver function, which may be prevented by endoscopic dilation of the stenoses. Controlled trials for evaluation of the beneficial effects of ursodeoxycholic acid treatment and of endoscopic measures in patients with major duct stenoses have become clinically difficult. Estimation of survival probabilities without treatment allows comparison of actuarial survival with the estimated survival probabilities.

METHODS/RESULTS: We studied survival in 65 patients with PSC treated with ursodeoxycholic acid (750 mg/day) and by endoscopic measures whenever necessary. Patients with decompensated cirrhosis in whom transplantation was foreseen were excluded. The study was started in May 1987 and the mean follow-up period was 45.0+/-3.5 (mean+/-SEM) months. Liver histology was performed in each of the patients before entry into the study and revealed that 21% were in stage 1, 37% in stage 2, 21% in stage 3 and 20% in stage 4. Of 65 patients, 12 had major duct stenosis at entry and another 11 developed major duct stenosis during ursodeoxycholic acid treatment, which was successfully treated by repeated endoscopic balloon dilations. The actuarial Kaplan-Meier survival probabilities without liver transplantation after treatment with ursodeoxycholic acid and dilation of major duct stenoses were significantly improved compared to the predicted survival rates with p=0.001.

CONCLUSIONS

Ursodeoxycholic acid does not prevent major bile duct occlusion. When ursodeoxycholic acid treatment and endoscopic opening of duct stenoses are combined, survival may be significantly improved.

摘要

背景/目的:原发性硬化性胆管炎的特征是肝内和肝外胆管进行性纤维性炎症和闭塞。熊去氧胆酸治疗可改善胆汁淤积的生化指标,部分还可改善肝脏组织学。治疗期间,主要胆管梗阻可能导致肝功能恶化,可通过内镜扩张狭窄部位来预防。评估熊去氧胆酸治疗和内镜措施对主要胆管狭窄患者的有益效果的对照试验在临床上已变得困难。估计未经治疗的生存概率可将精算生存率与估计的生存概率进行比较。

方法/结果:我们研究了65例接受熊去氧胆酸(750毫克/天)治疗并在必要时采取内镜措施的原发性硬化性胆管炎患者的生存情况。预计进行移植的失代偿性肝硬化患者被排除。该研究于1987年5月开始,平均随访期为45.0±3.5(平均值±标准误)个月。每位患者在进入研究前均进行了肝脏组织学检查,结果显示21%处于1期,37%处于2期,21%处于3期,20%处于4期。65例患者中,12例在入组时存在主要胆管狭窄,另外11例在熊去氧胆酸治疗期间出现主要胆管狭窄,通过反复内镜球囊扩张成功治疗。与预测生存率相比,熊去氧胆酸治疗和主要胆管狭窄扩张后未经肝移植的精算Kaplan-Meier生存概率显著提高,p = 0.001。

结论

熊去氧胆酸不能预防主要胆管闭塞。当熊去氧胆酸治疗与内镜下胆管狭窄开放相结合时,生存率可能会显著提高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验